Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.07% $40.20
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 456.69 mill |
EPS: | -2.52 |
P/E: | -15.95 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 61.11 mill |
Avg Daily Volume: | 0.807 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.95 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.71x |
Company: PE -15.95 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0274 (-100.07%) $-40.23 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 38.09 - 42.31 ( +/- 5.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-14 | Booth Bruce | Sell | 34 473 | Common Stock |
2024-03-14 | Booth Bruce | Sell | 10 846 | Common Stock |
2024-03-14 | Booth Bruce | Sell | 781 | Common Stock |
2024-03-15 | Booth Bruce | Sell | 8 126 | Common Stock |
2024-03-15 | Booth Bruce | Sell | 49 591 | Common Stock |
INSIDER POWER |
---|
46.08 |
Last 99 transactions |
Buy: 3 034 623 | Sell: 1 008 904 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $40.20 (0.07% ) |
Volume | 0.521 mill |
Avg. Vol. | 0.807 mill |
% of Avg. Vol | 64.60 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $33.94 | N/A | Active |
---|
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.